Because positron emission tomography (PET) takes advantage of cell metabolism, cell division, and receptor binding to depict functional processes with well-known high sensitivity, new receptor-targeted agents for imaging prostate cancer (such as prostate-specific membrane antigen, PSMA) can add high specificity. This evidence concerns the gene FOLH1 and prostate carcinoma.